Format

Send to

Choose Destination
Breast. 2019 Apr;44:29-32. doi: 10.1016/j.breast.2018.12.010. Epub 2018 Dec 20.

Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.

Author information

1
NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA.
2
White Plains Hospital, White Plains, NY, USA.
3
Frederick National Laboratory for Cancer Research, Rockville, MD, USA.
4
Foundation Medicine, Inc., Cambridge, MA, USA.
5
NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA; Department of Population Health, NYU School of Medicine, USA.
6
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
7
UC San Diego Moores Cancer Center, La Jolla, CA, USA.
8
Division of Cancer Treatment & Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
9
Institute of Pathology, Charité University Hospital, Berlin, Germany.
10
NYU Langone Health, Perlmutter Cancer Center, New York, NY, USA. Electronic address: sylvia.adams@nyulangone.org.

Abstract

Metaplastic breast cancer (MPBC) is a rare subtype that accounts for <1% of all breast cancers. Although these are typically "triple negative," they are relatively chemotherapy-refractory compared to conventional triple negative invasive breast cancers with more aggressive features and an overall poor prognosis. MPBC is a heterogeneous group of tumors that are enriched for TP53 and PIK3CA mutations, and have been found to have high PD-L1 expression though the mechanisms underlying its immunogenicity remain unclear. We perform comprehensive genomic profiling in the largest MPBC dataset (n = 192) to date and assess for other potential biomarkers of immune response.

KEYWORDS:

Genomic profiling; Metaplastic breast cancer; Triple negative; Tumor-infiltrating lymphocytes

PMID:
30609392
DOI:
10.1016/j.breast.2018.12.010
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center